Experimental combo targets Hard-to-Treat blood cancer
NCT ID NCT06735664
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial is testing whether combining two drugs—zanubrutinib and odronextamab—is safe for people with Richter's transformation, a rare and aggressive form of blood cancer that arises from chronic lymphocytic leukemia. The study will enroll 23 adults and monitor for side effects and signs that the cancer shrinks or disappears. The goal is to find a tolerable dose and see if this approach is worth studying further.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zanubrutinib and odronextamab
What this could lead to
If this combination proves safe and effective, it could offer a new treatment option for people with Richter's transformation, a rare and aggressive blood cancer.
What could go wrong
This is a very early Phase 1 trial with only 23 participants, so the main goal is safety, not effectiveness. The combination may cause serious side effects like cytokine release syndrome, and it may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact